Elan: Antegren study 'positive'

Pharmaceutical company Elan and its partner Biogen have said trial results from their Multiple Sclerosis treatment Antegren have been positive, having reduced the rate of relapses by 66%.

Elan and Biogen have submitted applications for the approval of Antegren as an MS treatment in the US, EU, Canada and Australia. The results released today are from one year of trials in an international study of 942 patients.